Where AI Actually Works in Biotech

The industry has plenty of new ideas. What it lacks is the systems to turn complex data into clear decisions.

Artificial intelligence frequently comes up as the answer. However, the actual results vary. Some projects show a clear return on investment. Others never leave the testing phase. The difference is never the AI model itself. The difference is how and where teams apply the technology.

At Sigma Software, we work with biotech groups that want practical results. These organizations need systems that work in the real world, integrate with current databases, and guide key clinical decisions. Based on proven use cases and our own engineering experience, this article outlines exactly where artificial intelligence currently provides real value in biotechnology.

AI Adoption in Biotech: The Shift From Experimentation to Practical Use

During the last ten years, biotech firms spent heavily on artificial intelligence. Many of those early projects were just tests.

That testing period is over.

Research from McKinsey shows that artificial intelligence could create between $60 billion and $110 billion in value every year for pharmaceutical and medical companies. At the same time, bringing a single new drug to market costs between $1 billion and $2.8 billion.

Consequently, executives no longer ask if they should use artificial intelligence. They ask where it actually works.

Clinical Trials: Where Small Improvements Create Large Impact

A company might spend years planning a clinical trial, only to hit a wall during patient recruitment. This remains a highly expensive bottleneck. Artificial intelligence directly solves this problem.

Instead of reading patient files one by one, software scans electronic health records to find matching patients instantly. Therefore, trials start faster and include better candidates.

Furthermore, the technology improves the initial trial design. By looking at past data, software spots bad inclusion criteria and predicts failure risks before the trial even opens.

The operational impact is clear. Industry data shows a 35 to 45 percent productivity boost in clinical development. Additionally, teams have cut Phase III timelines by about 30 percent. These are major gains that lower total research costs and speed up time to market.

However, algorithms alone cannot do this work. Teams need custom software that connects to electronic health records, organizes messy data, and follows strict healthcare rules. Many projects fail precisely because they lack this custom integration.

Managing Genomic Data at Scale for Precision Medicine

Genomics poses a completely different problem. The issue here is scale. A single human genome holds billions of data points. Reading this information manually is impossible, especially when you mix it with broader population data. Artificial intelligence makes this volume manageable.

The software identifies clinical genetic variants, groups patients by their genetic makeup, and finds patterns that point to new biomarkers.

Consequently, this changes therapy development. Instead of making drugs for everyone, companies can build targeted treatments for specific patient groups. Precision medicine becomes a daily reality instead of a future concept.

However, genomics requires heavy infrastructure. Models need massive computing power, highly secure databases, and direct connections to sequencing machines. Without this technical base, even the best models fail in clinical settings. For most companies, the main obstacle is not writing the algorithm. The main obstacle is building the required system around it.

Improving Early Drug Discovery with Predictive Models

Drug discovery gets the most media attention. The goal is simple. Companies want to find viable drugs faster and prevent late-stage failures.

In reality, artificial intelligence works by improving early choices. Software analyzes biological data to find good targets. It generates molecular options and predicts toxicity before anyone enters a lab.

This process keeps weak candidates out of the pipeline. Research shows these tools can reduce early-stage timelines by up to one-third. Specific real-world examples are even better. Certain AI-guided programs pushed drug candidates into clinical trials in just 18 months, compared to the normal 42 months.

However, expectations must remain grounded. Software does not replace physical lab tests or human trials. It simply improves the choices researchers make before those expensive stages start. This distinction helps leaders set realistic budgets and timelines.

Real-World Data: Understanding What Happens After Approval

When a drug finally hits the market, the job changes. Teams must track how the drug actually performs.

This is where real-world data becomes critical. Software reviews large data sets from clinical notes, insurance claims, and wearable monitors to see how treatments work outside of a controlled trial.

This tracking improves safety monitoring, updates treatment plans, and gives evidence to insurance payers and regulators. As government rules get stricter, providing real-world evidence is now a strict requirement, not just a bonus.

Automating Operational Workflows to Increase Biopharma Efficiency

Most people talk about research and development. However, many biotech groups see faster profits from basic operational updates. Artificial intelligence automates heavy paperwork, speeds up regulatory filings, and fixes supply chain routes.

Analysts expect generative models to create up to $7 billion in yearly value across biopharma operations. These updates are rarely glamorous, but they provide highly predictable financial returns.

Common Barriers to Successful AI Implementation in Biotech

Despite the obvious benefits, many biotech software projects never launch. Common reasons for failure include:

• Data scattered across different systems.
• No plan for system integration.
• Ignoring regulatory rules until the last minute.
• Models that break in real-world conditions.

Additionally, a massive gap exists between lab performance and daily reliability. Many models work perfectly in a test environment but fail when given real patient data. These failures are architectural problems, not math problems.

How Sigma Software Approaches AI in Biotech

At Sigma Software, we focus on making systems work in actual clinical settings. We start by looking at the business problem, not the newest technology. Our process includes:

• Data pipelines first: We take messy, scattered data and turn it into clean, structured systems.
• Integration by design: We link new software directly to electronic health records, lab systems, and research tools.
• Compliance from the start: We follow healthcare data regulations from the very first day of coding.
• Scalable architecture: We build frameworks that expand as your data and patient volume grow.

This structured process helps our partners move past basic testing and deploy software that drives actual medical decisions.

What Biotech Leaders Should Focus On Next

The most successful companies do not run the most experiments. They focus on solving the correct problems. This means leadership should:

• Build a strong data infrastructure before buying advanced models.
• Target high-value areas like genomics and clinical trials.
• Require all systems to be compliant and easy to explain.
• Hire partners who understand both software engineering and the healthcare industry.

Managing the Practical Reality of AI in Biotech

Artificial intelligence delivers its strongest returns in biotech when applied to data-heavy domains like clinical trial optimization, genomic data analysis, and drug discovery. These areas allow machine learning to solve specific problems where traditional methods often fail.

Focus on Systems, Not Just Models

The primary hurdle for biotech today is not a lack of models but a lack of infrastructure. For software to be effective, it must be supported by systems that ensure data integrity, meet regulatory standards, and scale across an organization.

• Prioritize Integration: Move beyond isolated pilots and embed the software into active research workflows.
• Focus on Utility: Build the underlying architecture that makes results consistent and reliable.

At Sigma Software, we specialize in this transition. We help organizations design solutions that function as core components of clinical and research processes.

Strategic Next Steps

To see results, focus on proven use cases and invest in the technical foundation required to make software usable in practice. Success lies in the final stage of implementation, where software meets science.

How are you currently balancing the need for new models with the practical challenge of integrating them into your existing research workflows?

• #AI/ML
• #Healthcare